Wall Street analysts predict that Beigene Ltd (NASDAQ:BGNE) will report earnings of ($3.01) per share for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Beigene’s earnings, with estimates ranging from ($3.20) to ($2.87). Beigene reported earnings per share of $2.54 in the same quarter last year, which suggests a negative year over year growth rate of 218.5%. The company is scheduled to announce its next quarterly earnings report on Monday, November 12th.
According to Zacks, analysts expect that Beigene will report full year earnings of ($10.86) per share for the current financial year, with EPS estimates ranging from ($11.50) to ($9.87). For the next fiscal year, analysts forecast that the business will report earnings of ($11.56) per share, with EPS estimates ranging from ($13.61) to ($8.40). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that follow Beigene.
Beigene (NASDAQ:BGNE) last announced its earnings results on Thursday, August 9th. The company reported ($2.92) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($2.12) by ($0.80). The business had revenue of $52.80 million for the quarter, compared to analyst estimates of $22.53 million. Beigene had a negative return on equity of 24.14% and a negative net margin of 75.19%. The company’s quarterly revenue was up 5279999900.0% compared to the same quarter last year. During the same period in the previous year, the company earned ($1.52) earnings per share.
Several research analysts have recently weighed in on the company. BidaskClub downgraded Beigene from a “buy” rating to a “hold” rating in a research note on Thursday, August 2nd. Maxim Group reaffirmed a “buy” rating and set a $225.00 target price on shares of Beigene in a research note on Monday, July 30th. ValuEngine raised Beigene from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, October 2nd. Piper Jaffray Companies set a $200.00 target price on Beigene and gave the stock a “buy” rating in a research note on Monday, July 23rd. Finally, Leerink Swann assumed coverage on Beigene in a research note on Monday, September 24th. They issued an “outperform” rating and a $215.00 price objective for the company. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Beigene has a consensus rating of “Buy” and an average price target of $186.34.
Shares of BGNE stock opened at $130.09 on Friday. The company has a debt-to-equity ratio of 0.16, a current ratio of 8.14 and a quick ratio of 8.10. The company has a market cap of $5.95 billion, a PE ratio of -58.34 and a beta of 0.66. Beigene has a 1-year low of $77.54 and a 1-year high of $220.10.
In related news, CMO Amy C. Peterson sold 5,769 shares of the stock in a transaction on Thursday, August 23rd. The stock was sold at an average price of $169.12, for a total value of $975,653.28. Following the completion of the transaction, the chief marketing officer now directly owns 4,661 shares of the company’s stock, valued at approximately $788,268.32. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Xiaodong Wang sold 3,449 shares of the stock in a transaction on Monday, August 13th. The shares were sold at an average price of $158.77, for a total value of $547,597.73. The disclosure for this sale can be found here. Over the last three months, insiders sold 14,129 shares of company stock valued at $2,389,512. 14.10% of the stock is owned by corporate insiders.
Large investors have recently modified their holdings of the business. Tower Research Capital LLC TRC grew its holdings in Beigene by 5,558.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 679 shares of the company’s stock valued at $104,000 after buying an additional 667 shares in the last quarter. Rockefeller Capital Management L.P. purchased a new stake in Beigene in the 2nd quarter valued at $135,000. K.J. Harrison & Partners Inc purchased a new stake in Beigene in the 3rd quarter valued at $207,000. Virtu Financial LLC purchased a new stake in Beigene in the 2nd quarter valued at $212,000. Finally, Northern Trust Corp purchased a new stake in Beigene in the 1st quarter valued at $302,000. Institutional investors own 77.75% of the company’s stock.
Beigene Company Profile
BeiGene, Ltd. develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer. Its commercial products include ABRAXANE, a chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancer; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia.
Read More: How to Use a Moving Average for Trading
Get a free copy of the Zacks research report on Beigene (BGNE)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.